Study S000211

Identify the Expanded Access Program, if Any. This is Required Unless the Expanded Access Type is "Individual Patients." A Randomized, Parallel, Double-blind, Placebo-controlled Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JMT206 Injection Alone or in Combination With Semaglutide in Obese Participants

ClinicalTrials.gov record

Registration

Registration: NCT07840729
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: NOT_YET_RECRUITING
Enrollment: 90
Start: 2026-10-20
Primary completion: 2027-02-28
Lead sponsor: Shanghai JMT-Bio Inc.
Conditions: Valid MeSH Conditiongs
Interventions: DRUG:JMT206 injection; COMBINATION_PRODUCT:Semaglutide injection; DRUG:Placebo injection
Results posted: FALSE

Registered primary outcomes

Incidence of Adverse Events (AE) assessed by CTCAE v6.0 [Baseline through week 19]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.